Phison Elevates Technology Solutions in 2022
Powerful Partnerships and Best-in-Class SSDs Showcase Phison’s Technology Leadership SAN JOSE, Calif.–(BUSINESS WIRE)–#enterprisessd—Phison Electronics Corp….
Month: November 2022
DataCore Software Named a Finalist for CRN’s 2022 Tech Innovator Award
READING, UK November 14, 2022 – DataCore Software today announced that CRN®, the US brand…
BrightInsight Inks Enterprise Agreement with CSL Behring for Digital Health Solutions Across Brand Portfolio
Following success of Hizentra App, CSL Behring and BrightInsight expand partnership to build apps for…
Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update
Continued Progress in Pepinemab Oncology and Neurology Clinical Programs Promising initial responses in Phase 1b/2…
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial Results
Ongoing INOpulse® REBUILD Phase 3 trial enrollment completion expected in the first quarter of 2023,…
Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
22nd Century Group (Nasdaq: XXII) to Participate in November 2022 Investor Conferences
BUFFALO, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a…
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial Results
– Cash Position of $21.3 Million as of September 30, 2022 – – Hosting Phase…
Virbac : Declaration of the number of shares and voting rights 10/2022
DECLARATION OF THE NUMBER OF SHARES AND VOTING…
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
– SHINE Alzheimer’s Trial Expands to European Sites – – SEQUEL Alzheimer’s Trial Awarded Additional…
Immutep Receives Australian R&D Tax Incentive
Media Release (Code: ASX: IMM; NASDAQ: IMMP) SYDNEY, AUSTRALIA, Nov. 14, 2022 (GLOBE NEWSWIRE) —…
ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Continued execution to advance exebacase and CF-370 into new clinical studies YONKERS, N.Y., Nov. 14,…
Revolo Biotherapeutics to Present at TIDES Europe 2022
NEW ORLEANS and LONDON, Nov. 14, 2022 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (“Revolo” or the…
MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs
Financing led by Wellington Management with participation from other leading healthcare funds CARMEL, Ind., Nov….
Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results
— Achieved key clinical and regulatory milestones across clinical pipeline, including the completion of enrollment…
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a…
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update Global trial…
IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update
Conference Call Today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) —…
Universe Pharmaceuticals INC Regains Compliance with Nasdaq Minimum Bid Price Requirement
Ji’an, Jiangxi, China, Nov. 14, 2022 (GLOBE NEWSWIRE) — Universe Pharmaceuticals INC (the “Company”) (Nasdaq:…
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Paltusotine’s Phase 3 PATHFNDR-1 trial in acromegaly fully enrolled and on track for topline data…